Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9208233 | 0.71 | MAPT (0.50) | ALDH1A1 | |
| SCHEMBL8557822 | 0.71 | BRPF1 (0.50) | KDM4EALDH1A1LMNA | |
| SCHEMBL21831539 | 0.68 | GPR3 (0.32) | KDM4EALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3482983 | 0.68 | CASP1 (0.34) | KDM4EMEN1NPC1RAB9AKMT2A | |
| SCHEMBL1419206 | 0.67 | NQO2 (0.34) | — | |
| SCHEMBL4006181 | 0.67 | KDM4E (0.42) | KDM4EALDH1A1LMNAMEN1NPC1 | |
| SCHEMBL29378766 | 0.66 | KMT2A (0.55) | KDM4EALDH1A1LMNAMEN1NPC1 | |
| SCHEMBL154592 | 0.66 | KMT2A (0.55) | KDM4EALDH1A1LMNAMEN1NPC1 | |
| Ammonia Solution, Strong SCHEMBL28142197 | 0.64 | KMT2A (0.53) | KDM4EALDH1A1LMNAMEN1NPC1 | |
| SCHEMBL1092872 | 0.63 | ALKBH5 (0.42) | KDM4EALDH1A1LMNAMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3625223-B1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-11 | — | — | EP | claimed |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2020-04-09 | — | — | US | claimed |
| CN-110621667-A | Pyrimidine derivatives | 爱杜西亚药品有限公司 | 2019-12-27 | — | — | CN | claimed |
| EP-3625223-B1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-11 | — | — | EP | disclosed |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2020-04-09 | — | — | US | disclosed |
| CN-110621667-A | Pyrimidine derivatives | 爱杜西亚药品有限公司 | 2019-12-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | PTGER1, PTGER4, PTGER2 | KDM4E 1545/4885ALDH1A1 418/4885LMNA 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.